Paperonium

Lung cancer · Lancet Reg Health Eur · 2025

Summary: immunotherapy linked to bigger second-cancer drop, 53% vs 30%. Results: targeted therapy, 44% vs 23%.

How much lowerThe summaryIts results53%Immunotherapy23%Immunotherapy30%Targeted therapy44%Targeted therapy
How much lowerThe summaryIts results53%Immunotherapy23%Immunotherapy30%Targeted therapy44%Targeted therapy

Drop in second-cancer risk versus chemotherapy, after adjusting

The paper says

The summary says patients’ risk of a second, different cancer (not the lung cancer coming back) was 53% lower on immunotherapy (immune-boosting drugs) than on chemotherapy, and 30% lower on targeted therapy (drugs aimed at a faulty gene), after adjusting for differences such as age.

Its own data show

The results section gives two versions. Adjusted: 23% lower for immunotherapy, 44% for targeted therapy. Unadjusted: 53% for targeted therapy, 30% for immunotherapy. The summary gives the unadjusted pair, each on the wrong drug. Simply counting also puts targeted therapy first: 1.5% of its patients got a second cancer, 2.1% on immunotherapy, 2.9% on chemotherapy.

Patients on each drug can differ in age, sex or smoking history; the paper itself says this likely sways the comparison. An adjusted figure tries to allow for such differences; an unadjusted one does not. Readers usually take numbers from the summary, where immunotherapy looks best; adjusted, targeted therapy does. Both are still linked to fewer second cancers than chemotherapy.

“The summary” means the paper’s abstract: the short summary printed at its top, which is the part most readers see.

Read the paper →Full technical write-up →

Incidence of second primary cancers in lung cancer survivors by oncological treatment: a nationwide prospective cohort study in Spain · Lancet Reg Health Eur (2025) · doi:10.1016/j.lanepe.2025.101402